ACC 2020 Ticagrelor monotherapy after 3-months DAPT reduces net adverse clinical events compared with continued DAPT in ACS patients who underwent PCI with drug-eluting stents (DES).
ACC 2020 After an initial 3 months of DAPT, ticagrelor monotherapy after complex PCI lowered bleeding without increasing risk of ischemic events compared to continued use of DAPT.
ACC 2020 Prof. Verheugt discusses the results of prespecified analyses of the TWILIGHT trial, in those with diabetes and those with complex PCI (the TWILIGHT-COMPLEX study).
ACC 2020 The TAILOR-PCI trial showed that genotype-guided antiplatelet therapy reduced ischemic events by 34% in patients who underwent PCI compared to conventional therapy.
An analysis of data of the dal-OUTCOMES trial shows that concentration of HDL particles is not associated with risk of MACE in patients after ACS.
The ICONIC study provides support for the hypothesis that higher-density calcified plaques are more stable, as patients who had ACS had lower high-density plaque volume than those without an event.
This observational study of ACS patients after PCI showed that ticagrelor was not associated with lower MACE compared to clopidogrel, but was associated with more major bleeding and dyspnea.
Patients with ACS who received prasugrel before PCI, showed less endothelial dysfunction and platelet aggregation, while those on clopidogrel and ticagrelor did not, nor did treatment after PCI.
Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.
AHA 2019 Pre-procedural administration of colchicine vs. placebo did not reduce PCI-related myocardial injury or MACE at 30 days, but attenuated increase in IL-6 and hsCRP at 24 hours post-PCI.
Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.
A post-hoc analysis of the GLOBAL LEADERS trial in patient undergoing multivessel PCI showed that ticagrelor monotherapy reduced all-cause death or MI, without any difference in bleeding compared to standard DAPT regimen.